(Q33942512)

30 July 2017

Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer (English)

1 reference

inflammatory breast cancer

30 July 2017

1 reference

Wendy A Woodward

6

0 references

Gabriel N Hortobagyi

12

object named as

Gabriel N Hortobagyi

1 reference

30 July 2017

Massimo Cristofanilli

4

object named as

Massimo Cristofanilli

1 reference

30 July 2017

Takayuki Iwamoto

1

1 reference

30 July 2017

Giampaolo Bianchini

2

1 reference

30 July 2017

Yuan Qi

3

1 reference

30 July 2017

Anthony Lucci

5

1 reference

30 July 2017

James M Reuben

7

1 reference

30 July 2017

Junji Matsuoka

8

1 reference

30 July 2017

Yun Gong

9

1 reference

30 July 2017

Savitri Krishnamurthy

10

1 reference

30 July 2017

Vicente Valero

11

1 reference

30 July 2017

Fredika Robertson

13

1 reference

30 July 2017

W Fraser Symmans

14

1 reference

30 July 2017

Lajos Pusztai

15

1 reference

30 July 2017

Naoto T Ueno

16

1 reference

30 July 2017

language of work or name

English

0 references

publication date

9 December 2010

1 reference

Breast Cancer Research and Treatment

30 July 2017

1 reference

30 July 2017

125

1 reference

30 July 2017

3

1 reference

30 July 2017

785-795

1 reference

https://scigraph.springernature.com/pub.10.1007/s10549-010-1280-6

30 July 2017

0 references

cites work

A novel lung metastasis signature links Wnt signaling with cancer cell self-renewal and epithelial-mesenchymal transition in basal-like breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4109066

Essential role for eIF4GI overexpression in the pathogenesis of inflammatory breast cancer.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4109066

Molecular targets for treatment of inflammatory breast cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4109066

Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4109066

Supervised risk predictor of breast cancer based on intrinsic subtypes

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4109066

Distinct molecular phenotype of inflammatory breast cancer compared to non-inflammatory breast cancer using Affymetrix-based genome-wide gene-expression analysis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4109066

Molecular definition of breast tumor heterogeneity

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4109066

Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4109066

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4109066

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4109066

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4109066

Gene expression profiling identifies molecular subtypes of inflammatory breast cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4109066

Complement function in mAb-mediated cancer immunotherapy

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4109066

Update on the management of inflammatory breast cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4109066

Revision of the American Joint Committee on Cancer staging system for breast cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4109066

Significance analysis of microarrays applied to the ionizing radiation response

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4109066

Molecular cytogenetic analysis of 11 new breast cancer cell lines

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4109066

Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4109066

Molecular profiling of inflammatory breast cancer: identification of a poor-prognosis gene expression signature.

5 July 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1280-6

Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1280-6

Distinct molecular signature of inflammatory breast cancer by cDNA microarray analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1280-6

Extensions to gene set enrichment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1280-6

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1280-6

The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1280-6

Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1280-6

Effects of neurotransmitters on the chemokinesis and chemotaxis of MDA-MB-468 human breast carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1280-6

Neoadjuvant trastuzumab and docetaxel in breast cancer: preliminary results

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4109066

Sigma-2 receptor agonists activate a novel apoptotic pathway and potentiate antineoplastic drugs in breast tumor cell lines

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4109066

Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study

29 October 2018

1 reference

12 December 2020

Inflammatory breast cancer: the experience of the surveillance, epidemiology, and end results (SEER) program

1 reference

12 December 2020

Gene Expression Profiling for Molecular Characterization of Inflammatory Breast Cancer and Prediction of Response to Chemotherapy

1 reference

12 December 2020

Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer

1 reference

12 December 2020

Molecular heterogeneity of inflammatory breast cancer: a hyperproliferative phenotype

1 reference

12 December 2020

Phase II study of neoadjuvant docetaxel, vinorelbine, and trastuzumab followed by surgery and adjuvant doxorubicin plus cyclophosphamide in women with human epidermal growth factor receptor 2-overexpressing locally advanced breast cancer

1 reference

12 December 2020

10.1007/S10549-010-1280-6

Identifiers

DOI

1 reference

Dimensions Publication ID

30 July 2017

0 references

1 reference

30 July 2017

1 reference